Skip to main content

Table 3 Univariable analysis of possible factors affecting overall survival

From: Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin

  Number of patients (%) Median OS, months (95% CI) HR (95% CI) P value
Age
  < 65 90 (52.0%) 10.1 (7.6–11.4) 1.00  
  ≥ 65 83 (48.0%) 7.2 (6.0–10.0) 1.28 (0.92–1.78) 0.138
Sex (female/ male)
 Female 86 (49.7%) 10.1 (7.8–12) 1.00  
 Male 87 (50.3%) 7.1 (5.5–10.1) 1.22 (0.88–1.69) 0.234
ECOG
 0–1 164 (94.8%) 8.1 (7.1–10.3) 1.00  
 2 9 (5.2%) 7.5 (2.8-NE) 1.86 (0.94–3.68) 0.074
BMI
  > 25 136 (78.6%) 7.8 (6.6–9.7) 1.00  
  ≥ 25 37 (21.4%) 11.9 (7.1–15.1) 0.79 (0.53–1.18) 0.255
Stage
 IIIB/ IVA 9 (5.2%) 7.2 (2.1-NE) 1.00  
 IVB 164 (94.8%) 8.1 (7.1–10.3) 0.68 (0.35–1.35) 0.272
Charlson comorbidity index
  < 9 110 (63.6%) 9.7 (7.8–11.0) 1.00  
  ≥ 9 63 (36.4%) 6.4 (4.4–10.2) 1.23 (0.87–1.72) 0.237
Local invasion
 Liver 47 (27.2%) 7.7 (6.6–11.4) 1.47 (1.02–2.12) 0.040
 Extrahepatic bile duct 26 (15.0%) 6.5 (5.0–11.9) 1.06 (0.67–1.67) 0.812
 Intestine 20 (11.6%) 8.6 (5.0-NE) 0.79 (0.47–1.34) 0.386
 Peritoneum 2 (1.2%) 10.5 (2.3-NE) 0.94 (0.23–3.82) 0.933
 Hepatic artery 15 (8.7%) 6.4 (5.0-NE) 1.12 (0.63–1.98) 0.699
 Portal vein 11 (6.4%) 5.9 (2.3-NE) 1.17 (0.6–2.31) 0.643
Metastasis site
 Liver 74 (42.8%) 6.2 (5.3–10.0) 1.72 (1.23–2.41) 0.002
 Peritoneum 46 (26.6%) 6.5 (4.2–10.1) 1.25 (0.87–1.82) 0.229
 Lung 29 (16.8%) 7.2 (5.4–15.6) 0.85 (0.54–1.34) 0.487
 Bone or muscular system 14 (8.1%) 5.1 (3.3–13.1) 2.03 (1.14–3.61) 0.016
 Distant lymph node 102 (59.0%) 8.3 (6.5–10.9) 1.10 (0.79–1.54) 0.560
Total bilirubin
  ≤ 1.5 X ULN 130 (75.1%) 9.7 (7.8–11.0) 1.00  
  > 1.5 X ULN 43 (24.9%) 5.3 (3.7–9.5) 1.77 (1.21–2.58) 0.003
Transaminase
  ≤ 1.5 X ULN 120 (69.4%) 9.7 (7.8–11.5) 1.00  
  > 1.5 X ULN 53 (30.6%) 6.2 (4.5–9.7) 1.53 (1.07–2.18) 0.019
NLR
  ≤ 3 75 (43.4%) 12.4 (10.2–14.6) 1.00  
  > 3 98 (56.6%) 6.2 (4.8–7.8) 2.34 (1.66–3.29) < 0.001
PLR
  < 190 102 (59.0%) 10.3 (9.4–13.7) 1.00  
  ≥ 190 71 (41.0%) 6.6 (5.6–8.1) 1.77 (1.27–2.47) 0.001
CEA, ng/mL
  < 5 103 (59.5%) 10.3 (7.8–13.1) 1.00  
  ≥ 5 70 (40.5%) 6.5 (5.0–8.1) 1.87 (1.33–2.63) < 0.001
CA 19–9, U/mL
  < 500 114 (65.9%) 10.7 (9.0–13.3) 1.00  
  ≥ 500 59 (34.1%) 5.5 (4.1–7.6) 2.28 (1.61–3.23) < 0.001
  1. OS overall survival, HR hazard ratio, ECOG Eastern Cooperative Oncology Group, BMI body mass index, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, CEA carcinoembryonic antigen, CA 19–9 carbohydrate antigen 19–9, NE not estimable, ULN upper limit of normal